{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:29:55Z","timestamp":1791462595634,"version":"4.3.4"},"reference-count":17,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"33","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,11,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      In this multicenter, double-blind, phase III study, 418 patients with previously untreated, unresectable, stage III\/IV, wild-type BRAF melanoma were randomly assigned 1:1 to receive nivolumab 3 mg\/kg every 2 weeks or dacarbazine 1,000 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      every 3 weeks. The primary end point was overall survival (OS), and secondary end points included progression-free survival (PFS), objective response rate (ORR), and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Patients were followed for a minimum of 60 months from the last patient randomly assigned (median follow-up, 32.0 months for nivolumab and 10.9 months for dacarbazine). Five-year OS rates were 39% with nivolumab and 17% with dacarbazine; PFS rates were 28% and 3%, respectively. Five-year OS was 38% in patients randomly assigned to dacarbazine who had subsequent therapy, including nivolumab (n = 37). ORR was 42% with nivolumab and 14% with dacarbazine; among patients alive at 5 years, ORR was 81% and 39%, respectively. Of 42 patients treated with nivolumab who had a complete response (20%), 88% (37 of 42) were alive as of the 5-year analysis. Among 75 nivolumab-treated patients alive and evaluable at the 5-year analysis, 83% had not received subsequent therapy; 23% were still on study treatment, and 60% were treatment free. Safety analyses were similar to the 3-year report.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Results from this 5-year analysis confirm the significant benefit of nivolumab over dacarbazine for all end points and add to the growing body of evidence supporting long-term survival with nivolumab mono-therapy. Survival is strongly associated with achieving a durable response, which can be maintained after treatment discontinuation, even without subsequent systemic therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.20.00995","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T15:59:48Z","timestamp":1601481588000},"page":"3937-3946","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":235,"title":["Five-Year Outcomes With Nivolumab in Patients With Wild-Type\n                    <i>BRAF<\/i>\n                    Advanced Melanoma"],"prefix":"10.1200","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-0238","authenticated-orcid":false,"given":"Caroline","family":"Robert","sequence":"first","affiliation":[{"name":"Gustave Roussy, Villejuif, France"},{"name":"Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-3545","authenticated-orcid":false,"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Brady","sequence":"additional","affiliation":[{"name":"Cabrini Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Andr\u00e9 Centre Hospitalier Universitaire, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Di Giacomo","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[{"name":"University of Lille, INSERM U1189, Service de Dermatologie, Chu Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona M.","family":"McNeil","sequence":"additional","affiliation":[{"name":"Chris O\u2019Brien Lifehouse, Melanoma Institute Australia, and Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4791-8372","authenticated-orcid":false,"given":"Ewa Anna","family":"Kalinka","sequence":"additional","affiliation":[{"name":"Polish Mother\u2019s Memorial Hospital-Research Institute, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-7290","authenticated-orcid":false,"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, INSERM U976, and Dermatology and CIC, AP-HP, Saint Louis Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Charles","sequence":"additional","affiliation":[{"name":"Grenoble Alpes University Hospital, INSERM U1209, Grenoble Alpes University, Grenoble, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0139-4596","authenticated-orcid":false,"given":"Micaela M.","family":"Hernberg","sequence":"additional","affiliation":[{"name":"Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-9124","authenticated-orcid":false,"given":"Vanna","family":"Chiarion-Sileni","sequence":"additional","affiliation":[{"name":"Oncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Mihalcioiu","sequence":"additional","affiliation":[{"name":"Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Mauch","sequence":"additional","affiliation":[{"name":"University Hospital Cologne and Centrum f\u00fcr Integrierte Onkologie K\u00f6ln, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arance","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-9446","authenticated-orcid":false,"given":"Francesco","family":"Cognetti","sequence":"additional","affiliation":[{"name":"Regina Elena Institute, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-5958","authenticated-orcid":false,"given":"Lars","family":"Ny","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Comprehensive Cancer Center, University Hospital Essen, Essen, Germany"},{"name":"German Cancer Consortium, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0451-2885","authenticated-orcid":false,"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1164-4306","authenticated-orcid":false,"given":"Jes\u00fas","family":"Zoco","sequence":"additional","affiliation":[{"name":"Syneos Health, Braine l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Re","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[{"name":"Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Atkinson","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital, Woolloongabba, and Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","first-page":"488","volume":"23","author":"Bhatia S","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30388-2"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6270"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4514"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.2228"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz011"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30700-9"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.321"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0309-3"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy330"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12503"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0357-y"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.20.00995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T04:46:34Z","timestamp":1653799594000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.20.00995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":17,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2020,11,20]]}},"alternative-id":["10.1200\/JCO.20.00995"],"URL":"https:\/\/doi.org\/10.1200\/jco.20.00995","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"2020-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}